Jason was a California native until he abandoned the sunshine and traveled east. He attended Princeton University in New Jersey, receiving his A.B. in molecular biology in 1997. His thesis work with Dr. Thomas Shenk used adeno-associated virus vectors to create mutations in human cytomegolovirus. Jason received his Ph.D. from Harvard University working in the lab of Dr. Joseph Sodroski. His graduate thesis used HIV viral vectors to explore the role of HIV-1 envelope glycoproteins in viral pathogenesis, as well as to identify novel animal models for HIV research. Jason currently works for Decision Resources, Inc. as a business and market analyst for the pharmaceutical and biotech industry. He enjoys spending his free time with his wife Michelle, daughter Emily, and small dog Peanut.
Kim is Executive Vice President, Head of Business & Corporate Development at Repare Therapeutics, Inc., a precision oncology company focused on Synthetic Lethal mechanisms in DNA Damage Repair (DDR) and genome instability. Prior to Repare, he was Chief Business Officer and Chief Operating Officer at Resilience Therapeutics and CBO at Epirus Biopharmaceuticals. He was previously Executive Director at Pfizer, where he helped lead the design and execution of the R&D operational turnaround post-Wyeth acquisition and led strategic efforts to enter and expand into new markets, as a member of the Worldwide R&D Strategy Leadership Team. In this capacity he initiated and led the strategy development and operational launch of Pfizer’s integrated, pan-enterprise Immuno-Oncology platform. Prior to Pfizer, he was Vice President at Goldman Sachs, covering the global Specialty and Large Cap Pharmaceutical sectors. Prior to Goldman, Kim led licensing and M&A activities at Epix Pharmaceuticals, including the ~$130M acquisition of Predix Pharmaceuticals in 2006. Kim was also the founding CEO and President of Xpogen, Inc., a venture-backed bioinformatics company he co-founded while in graduate school.
Kim received his AB cum laude in Economics from Harvard College and his Ph.D. in Neurobiology from Harvard University. His thesis work focused on the molecular genetics and mechanisms of transcriptional regulation of the gene for corticotropin- releasing hormone (CRH).
Peter Kolchinsky is a co-founder and General Partner of RA Capital Management, which has been investing in healthcare companies since 2002. He is a member of the National Academies Board on Global Science and Technology, authored an e-book titled “The Entrepreneur’s Guide to a Biotech Startup”, and serves as an advisor to startup companies and non-profits. Peter received his undergraduate degree in Biology from Cornell University and a Ph.D. in Virology from Harvard University, where he conducted research at Dana-Farber Cancer Institute on the entry mechanism of Human Immunodeficiency Virus (HIV).